This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04888/identifier/chemspider/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB04888/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/resource/drugbank/drug/DB04888/identifier/bindingdb/
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04888/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04888/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB04888/identifier/drugbank/

Statements

Subject Item
n2:DB04888
rdf:type
n3:Drug
n3:description
Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism. [Wikipedia]
n3:generalReferences
# Newman-Tancredi A, Cussac D, Depoortere R: Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs. 2007 Jul;8(7):539-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17659474 # Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T: Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol. 2007 Aug 9;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17692841
n3:group
investigational
n3:indication
Bifeprunox is being evaluated for the treatment of schizophrenia, psychosis, and Parkinson's disease.
owl:sameAs
n6:DB04888
dcterms:title
Bifeprunox
adms:identifier
n8:208951 n9:14878213 n10:181044 n11:DB04888 n12:Bifeprunox n14:50241119
n3:mechanismOfAction
In contrast to D2 receptor antagonism, partial D2 agonism is believed to decrease dopamine activity in an overactive dopamine system while simultaneously increasing dopamine activity in regions of the brain where dopaminergic activity is too low. By blocking overstimulated receptors and stimulating underactive ones, partial D2 agonists act as dopamine stabilisers. In common with aripiprazole, bifeprunox also acts as a serotonin, 5-HT1A agonist. This property may contribute to efficacy against the negative symptoms of schizophrenia and reduce the likelihood of extrapyramidal symptoms (EPS).
n3:synonym
Bifeprunox mesilate Bifeprunoxum
n3:IUPAC-Name
n4:271B5D44-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5D4A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5D49-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5D46-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5D47-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5D48-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5D42-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5D43-363D-11E5-9242-09173F13E4C5 n4:271B5D40-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5D41-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5D50-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5D51-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5D4B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5D4C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5D4E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5D4D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5D4F-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
350992-10-8
n3:Bioavailability
n4:271B5D56-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5D58-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5D59-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5D55-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5D54-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5D57-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5D45-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5D52-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5D53-363D-11E5-9242-09173F13E4C5